Shuttle Pharma Announces Phase 2 Clinical Trial Of Ropidoxuridine For Glioblastoma Now Open For Enrollment At Two Sites, Receives FDA Orphan Drug Designation, And Regains Nasdaq Compliance After Filing Delayed Financial Reports
Shuttle Pharma Announces Phase 2 Clinical Trial Of Ropidoxuridine For Glioblastoma Now Open For Enrollment At Two Sites, Receives FDA Orphan Drug Designation, And Regains Nasdaq Compliance After Filing Delayed Financial Reports
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.